Evaluation of risk factors for development of complications in Type II diabetes in Europe

The Cost of Diabetes in Europe - Type II study is the first large coordinated attempt to measure the current standard of care and determine the costs of managing patients with Type II (non-insulin-dependent) diabetes mellitus. The study evaluated glycaemic control, blood lipid levels and blood press...

Full description

Saved in:
Bibliographic Details
Published in:Diabetologia 2002-07, Vol.45 (7), p.S23-S28
Main Authors: LIEBL, A, MATA, M, ESCHWKGE, E
Format: Article
Language:English
Subjects:
Associated diseases and complications
Biological and medical sciences
Blood Glucose - metabolism
Blood Pressure
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Diabetes. Impaired glucose tolerance
Diabetic Angiopathies - blood
Diabetic Angiopathies - epidemiology
Diabetic Angiopathies - physiopathology
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Europe - epidemiology
Glycated Hemoglobin A - analysis
Guidelines as Topic
Humans
Lipids - blood
Medical sciences
Risk Factors
Triglycerides - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Cost of Diabetes in Europe - Type II study is the first large coordinated attempt to measure the current standard of care and determine the costs of managing patients with Type II (non-insulin-dependent) diabetes mellitus. The study evaluated glycaemic control, blood lipid levels and blood pressure, all of which are risk factors for complications. Records of these clinical characteristics were collected from over 7000 patients during the 6-month study period. The mean HbA(1c) value for the entire study population was 7.5%, ranging from 7.0% in Sweden to 7.8% in the United Kingdom. Only 31% of individuals achieved good glycaemic control (HbA(1c)< or = 6.5%) according to current European guidelines. Only 64% of the total study population were tested for HbA(1c) values at least once within the 6-month study period (ranging from 49% in Spain to 71% in the UK), although HbA(1c) testing every 3 months is recommended for all patients, by European Diabetes Policy Group guidelines. The majority of patients had borderline total cholesterol values, with a mean value of 5.7 mmol/l. Overall, 21% of patients were classified as having low risk cholesterol levels (
ISSN:0012-186X
1432-0428
DOI:10.1007/s00125-002-0863-0